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Abstract Vitamin D3, or cholecalciferol, is the naturally
occurring form of vitamin D that is converted in the skin
and hydroxylated in the liver and kidney to the active form
found in humans. The main role for vitamin D is calcium
homeostasis, and low levels of vitamin D result in lower
gastrointestinal absorption of calcium. Vitamin D is also
critical for mineralization of bone tissue, muscle function,
and coordination. Recent studies have found prevention of
bone mass loss and reduction in falls and fractures in
patients supplemented with vitamin D. A high percentage
of systemic lupus erythematosus patients are reported to
have insufficient or deficient levels of vitamin D. This
paper reviews the biology of vitamin D, its role in calcium
homeostasis, and how it contributes to the maintenance of
bone, muscle, and joint function in older adults and
individuals with systemic lupus erythematosus.
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Introduction
Vitamin D3, or cholecalciferol, is the naturally occurring
form of the vitamin and is also the active form found in
humans. In the skin, under the influence of UV light, 7-
dehydroxycholesterol is photoconverted to previtamin D3,
or cholecalciferol. The previtamin D3, bound to a vitamin
D–binding protein, is transported to the liver, where it is
hydroxylated to 25(OH)D3. In the kidneys, 25(OH)D3 is
further metabolized to 1,25 (OH)D3, the biologically active
form of vitamin D. The other form of vitamin D, vitamin
D2, or ergocalciferol, is found in plants and is much less
potent than vitamin D3. It is also biologically inert prior to
conversion in the liver and kidney to active 1,25 vitamin
D3. 1,25(OH)D3 is nearly 1000 times more potent than the
precursor of vitamin D2 or vitamin D3. The major source of
vitamin D is sun exposure; thus, active vitamin D in the
body can be affected by the season and the duration of
direct exposure to sunlight and can be inhibited by
sunscreen use and increased skin pigmentation.
In contrast to other vitamins, dietary intake is usually a
minor source of vitamin D and provides only about 100 IU/d.
Vitamin D is rarely found in foods other than eggs, fatty fish,
and supplemented dairy products. It can be supplied as a
component in combination vitamins or by individual supple-
ments that have become available [1].
Mechanism of Action
Vitamin D plays a critical role in calcium homeostasis.
Maintenance of calcium levels in the body is organized in a
balanced system, with vitamin D acting to produce enough
gastrointestinal absorption of calcium to satisfy calcium
demand and bone turnover. Low levels of vitamin D result
in the calcium reserves in bone being depleted in an attempt
to correct for the reduced calcium that will be absorbed
from the gut. When calcium absorption by bone is reduced
and vitamin D status is sufficient, absorption of dietary
calcium should be about 30% to 40%. As vitamin D levels
fall, absorption of dietary calcium declines to about 10% to
15% [2]. The reduction in intestinal calcium absorption
associated with low levels of vitamin D triggers the release
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of parathyroid hormone (PTH), which stimulates the
absorption of calcium through augmentation of the produc-
tion of 1,25(OH)2D [2, 3]. PTH also mediates the
mobilization of calcium from bone by stimulating bone
resorption, which results in a reduction in bone mineral
density. Chronic elevations of PTH from vitamin D
deficiency are associated with increased cortical bone
resorption and porosity.
The relationship between vitamin D status and calcium
absorption was recently studied in two small, randomized,
crossover studies of postmenopausal women. Study partic-
ipants received commercially available calcium supplements
providing about 500 mg of calcium and 200 IU of vitamin D
per day. The participants were predosed with 800 IU of 25
(OH)D on alternate days for an average of 3 weeks prior to
calcium absorptionmeasurements as a way to restore adequate
vitamin D levels rapidly [4]. Compared with women who
received no 25(OH)D treatment, those who did undergo this
treatment demonstrated a 3.5% higher (P<0.002) serum
calcium concentration prior to calcium supplement ingestion,
a 16.5% lower serum PTH concentration, and a 65% greater
increase in calcium absorption fraction.
Vitamin D and Muscle Function
During the past 10 to 20 years, many case reports have
documented that in both young and old individuals,
prolonged vitamin D deficiency can be associated with
severe muscle weakness and disability and has been found
to improve within several weeks of vitamin D supplemen-
tation [5, 6]. The findings from a population-based US
survey of 4100 ambulatory adults 60 years of age and older
suggest an association between vitamin D status and lower
extremity function [7]. Lower extremity function in study
participants was assessed using an eight-foot walking-speed
test, and serum 25(OH)D concentrations were determined
by radioimmunoassay. Test performance speed increased as
the 25(OH)D level rose throughout the reference range of
the assay of 9.0 to 37.6 ng/mL, with the most significant
improvement observed as 25(OH)D increased from about
10 to 17 ng/mL. Because this study used a cross-sectional
design to analyze the data, a causal relationship between
vitamin D concentration and lower extremity function
cannot be established.
The vitamin D receptor (VDR) is present in muscle cells,
and the number of VDRs on each muscle cell appears to
decrease with age [8]. Binding of vitamin D to its receptor
results in the activation of several signaling pathways,
including calcium uptake into the muscle cell, phosphate
transport across the cell membrane, phospholipid metabo-
lism, and muscle cell proliferation and differentiation [9••].
Studies in chick embryo myoblasts demonstrated that short-
term treatment with 1,25(OH)D at roughly physiologic
levels increased cell density and fusion of myocytes and
had stimulatory effects on their proliferation. However,
effects were not seen on the differentiation phase of
myocyte development [10]. Some data also support a role
for 1,25(OH)D in modulating muscle contractility [9••].
Recent studies in VDR knockout murine models provide
additional support for the direct effects of vitamin D and its
receptor on skeletal muscle tissue. The VDR-null mouse
(lacking the VDR) has a phenotype characterized by
reduced bone size, body size, weight, motor coordination,
and poor physical performance compared with wild-type
mice [11]. Also, metabolic abnormalities associated with
lack of the VDR include hypocalcemia, hypophosphatemia,
secondary hyperparathyroidism, bone deformity, and mus-
cle fiber changes. These features were more prominent in
the VDR-null mouse after weaning and with aging,
suggesting a role for the VDR in skeletal development
and maturation. However, VDR polymorphisms, which are
subtle variations in DNA sequence of the VDR gene, exist
that are associated with a range of biologic characteristics,
including muscle strength. The Fok1 polymorphism
involves a T/C transition in exon 2 of the VDR gene [12].
Individuals with the C allele have a shorter VDR than those
with the T allele, and there is in vitro evidence for enhanced
activity of VDR as a transcription factor. Clinically, the C
allele has been associated with reduced fat mass and
quadriceps strength [12]. More work may be warranted to
link signaling through the VDR in muscle with its potential
functional consequences.
Muscle biopsies from adults with profound vitamin D
deficiency had shown predominant type II fiber atrophy. As
type II muscle fibers are the initial fibers to be recruited for
balance and coordination, this may explain some of the
tendency for increased falls in individuals who are vitamin
D deficient. Histologic sections of type II muscle fibers
show enlarged interfibrillar spaces and infiltration of fat,
fibrosis, and glycogen granules [13, 14].
Two small studies have evaluated vitamin D supplemen-
tation and muscle fiber composition. One randomized
controlled clinical trial of older adult stroke victims found
that 1000 IU of vitamin D2 over a 2-year period increased
percentage and mean diameter of type II muscle fibers [14].
Furthermore, serum 25(OH)D level was correlated with
both the baseline type II muscle fiber diameter and the
diameter after 2 years of follow-up.
A few clinical trials have evaluated the combination of
calcium and vitamin D to determine whether this kind of
supplement might alter the risk of falling in older adults. A
double-blind, randomized trial in Switzerland studied the effect
of vitamin D and calcium supplementation on the risk of
falling among 122 women (mean age, 85.3 years) cared for in
long-term geriatric care units before transfer into nursing
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homes. Study participants were randomly assigned to receive
1200 mg/d of calcium alone or calcium 1200 mg/d plus
800 IU/d of vitamin D for 12 weeks. The mean serum 25(OH)
D concentration prior to treatment was 12 ng/mL in both
treatment groups. Vitamin D and calcium supplementation
accounted for a 49% reduction in the risk of a fall (P=0.01)
after adjusting for 1) age, 2) the number of participants who
fell during a 6-week pretreatment period, 3) the number of
falls per person during the pretreatment period, 4) baseline
serum levels of 25(OH)D and 1,25(OH)2D, and 5) the
observation time during treatment. This reduction may be
attributable to the significant improvement (P=0.0094) in
musculoskeletal function detected in patients who received
vitamin D and calcium. Because of a high number of
transfers to nursing homes, the dropout rate in this study
was high. All study participants were institutionalized older
European women from Switzerland, so the study results may
not be generalizable across a more broad population [15].
Bischoff et al. [15] performed a meta-analysis of several
small clinical studies that evaluated the effect of vitamin D
treatment compared with control groups on the risk of falling
and found that vitamin D replacement favored a reduction in
number of falls, with an overall OR of about 0.75.
Vitamin D and Bone Mass and Fractures
The most important determinants of the risk of skeletal
fracture are low bone mass, microarchitectural deterioration,
and a propensity to fall. Adequate vitamin D is critical for
bone formation. Higher levels of 25(OH)D have been
associated with higher bone mineral density at the hip in
young and older men and women from the Third National
Health and Nutrition Examination Survey at levels up to
36.8 ng/mL [16], and supplementation of vitamin D in older
adults also prevents bone loss [17]. A recent study from the
Women’s Health Initiative cohort also confirmed that women
who had a hip fracture had significantly lower 25(OH)D
values than controls. Also, women in the lowest quartile for
25(OH)D had a nearly 1.7-fold higher risk of hip fracture
than women in the higher quartile for 25(OH)D [18•].
Nutritional vitamin D deficiency causes insufficient
mineralization of bone tissue and rickets in growing children
and osteomalacia in adults. The active form of vitamin D,
1,25(OH)D, stimulates the absorption of calcium and
phosphorus from the gastrointestinal tract, thereby making
calcium and phosphorus available for mineralization. In mild
vitamin D deficiency, the elevation of serum PTH increases
the conversion of 25(OH)D to 1,25(OH)D to compensate for
the insufficient 25(OH)D available; however, elevation in
PTH increases bone resorption, leading to additional bone
loss [19]. Clinical osteomalacia usually is present with severe
vitamin D deficiency at levels of 5 ng/mL or less. The
clinical manifestations of osteomalacia include bone pain,
muscular weakness generally of the proximal shoulder and
hip girdle, and difficulty walking. If the calcium is also low
in patients with osteomalacia, symptoms of low calcium,
such as tetany or seizures, may be present. Fractures of the
bone may occur because the quality of the bone in
osteomalacia with reduced mineralization is more fragile
than bone of normal mineral quality. A transiliac bone
biopsy after fluorochrome labeling is required to confirm the
diagnosis of osteomalacia. The specimens should be stained
with Goldner or von Kossa stains for mineralizing surface.
The bone histology section has less than 5% nonmineralized
bone matrix or osteoid. However, with osteomalacia, the
osteoid surface may be as high as 70%, and bone resorption
may be slightly increased due to secondary hyperparathy-
roidism [19].
Vitamin D as a Treatment to Prevent Osteoporotic
Fractures
A randomized, double-blind trial in the United Kingdom
examined the effect of oral vitamin D supplementation on
the risk of fracture in 2686 men and women 65 to 85 years
of age who were living in the community. Study partic-
ipants were randomly assigned to receive a single oral dose
of 100,000 IU of vitamin D3 or matching placebo every
4 months for 5 years, which is equivalent to a daily dose of
about 800 IU. The incidence of fracture of the hip, wrist,
forearm, or vertebrae was 4.5% in volunteers assigned to
receive vitamin D and 6.5% in those given placebo (P=
0.02), and the age-adjusted relative risk of fracture at these
sites was 33% lower with vitamin D. To maximize
generalizability, exclusion criteria were minimal. However,
this approach introduces increased variables that can
hamper the interpretability of the findings. The data were
ascertained via self-report questionnaire, which could have
led to ascertainment errors [20]. In another study, institu-
tionalized older adult women in France were randomly
assigned to calcium and vitamin D, 800 IU/d, or placebo for
18 months. Hip and other nonvertebral fracture rates were
reduced by nearly 40% in the treated participants compared
with the placebo group [21].
Vitamin D Intake Requirements
In 1997, the Institute of Medicine of the National Academy
of Sciences made recommendations for vitamin D intake.
The recommendations are as follows:
& Adults up to 50 years of age: supplementation with
5 µg/d, or 200 IU
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& Adults 51 to 70 years of age: 10 µg/d, or 400 IU
& Adults older than 71 years of age: 15 µg/d, or 600 IU.
These recommendations are based on the amount of
vitamin D that is needed to maximally suppress PTH (1–
84) secretion [22], but there is no consensus, as some
investigators advocate that the 25(OH)2D level needed to
maximally suppress PTH is 30 to 44 ng/mL [23]. The
current recommendation for vitamin D supplementation
of 600 IU for men and women older than 71 years of
age is not sufficient to bring the level of 25(OH)D to 30 to
32 ng/mL, which is the level needed to lower fracture
risk. Given the need to reach 25(OH)D levels of at least
30 ng/mL, it is recommended that the supplementation be
enough to achieve this level. The National Academy of
Sciences has recommended that the safe upper limit of 25
(OH)D be 50 µg/d, or 2000 IU.
Vitamin D is available in two forms: ergocalciferol, or
D2 (the plant form), and cholecalciferol, or D3 (animal
origin). Studies have found that vitamin D3 increases serum
25(OH)D more effectively than vitamin D2 [24]. Therefore,
vitamin D3 is the preferred form for clinical use.
In summary, vitamin D is important for the maintenance
and function of the musculoskeletal system. As they age, or
due to nutritional deficiencies, many men and women need
supplementation to meet the daily requirements and
maintain normal serum concentrations. The general con-
sensus is that a 25(OH)D level of 20 ng/mL, or 75 nM or
higher, along with adequate calcium intake is needed to
lower fracture risk, maintain well-mineralized bone matrix
tissue, and maintain adequate muscle strength and function.
Most older adults will need to be supplemented with 800 to
1000 IU/d of vitamin D3 to reach this level.
Treatment Options for Patients With Vitamin D
Deficiency
Physicians and health care providers have several options
for treating vitamin D insufficiency or deficiency. A
loading dose of vitamin D can rapidly increase 25(OH)D
to the normal range, and in the clinic, we frequently
prescribe 50,000 IU of vitamin D once per week for about
8 weeks [23]. In our experience, the vitamin D levels often
decline without maintenance therapy, so we recommend
vitamin D doses of 400 to 1000 IU/d or to continue the
50,000 IU of vitamin D2 every 2 to 4 weeks. It is important
to evaluate patients with recurrent vitamin D deficiency for
evidence of fat malabsorption, celiac disease, or renal
disease, as these individuals may need treatment of their
underlying medical condition and possibly a higher
maintenance dose of vitamin D to maintain normal,
sufficient levels.
Vitamin D and Systemic Lupus Erythematosus Patients
Several recently published reports have indicated that a
high percentage of individuals with systemic lupus eryth-
ematosus have insufficient or deficient levels of 25(OH)D
[25, 26]. In practice, rheumatologists may be treating these
patients with vitamin D2 or D3 supplements to increase
serum levels of 25(OH)D to greater than 30 ng/mL.
Although several anecdotal reports note that raising the
serum concentrations to more than 30 ng/mL is associated
with improvement in musculoskeletal disease symptoms, a
formal clinical study has not yet been completed, although
the Immune Tolerance Network is conducting a study to
evaluate the effect of raising 25(OH)D levels on parameters
of autoimmunity and systemic lupus erythematosus activity.
Until the results of this trial are published, this author
suggests that replacement of 25(OH)D to levels greater than
32 ng/mL should maximize the absorption of calcium from
the gastrointestinal tract with reasonable suppression of
serum PTH levels.
Conclusions
Vitamin D is critical for bone and muscle function. At this
time, serum levels of 25(OH)D should be maintained at
32 ng/mL until further research determines whether higher
serum levels improve outcomes.
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